BioLeaders, Phase 2 Clinical Trial of BLS-H01 in Moderate COVID-19 Patients

[Asia Economy Reporter Minji Lee] BioLeaders announced on the 20th that it has applied to the Ministry of Food and Drug Safety for a Phase 2 clinical trial, which is a multicenter, randomized study to evaluate the efficacy and safety of BLS-H01 (poly-gamma-glutamic acid) in patients with moderate COVID-19.

The company stated, "This is to comparatively evaluate the efficacy and safety of BLS-H01 administration versus placebo in patients with moderate COVID-19," adding, "Unlike other treatments, BLS-H01 stimulates TLR4 present on the cell surface, promoting the secretion of IFN-β through signal transduction, thereby activating immune cells, producing antiviral proteins that inhibit viral replication, and inducing apoptosis in virus-infected cells."